BDX — Becton Dickinson
Price when we picked it (Mar 23, 2026)
$156.23
Target: $200.00 (+28%)
P/E Ratio
25.5
P/E Forward
12.5
Dividend
2.69%
Market Cap
$44.4B
EPS
$5.82
Consensus
Buy
What they do
Becton Dickinson makes the medical devices used by hospitals worldwide. It operates in 4 segments: Medical Essentials (syringes, needles, Vacutainer — 34% revenue), Interventional (surgery, urology, critical care — 28%), Connected Care (BD Alaris pumps, BD Pyxis dispensers — 25%), and BioPharma Systems (pre-filled syringes for GLP-1s and biologics — 13%). Present in ~200 countries.
Why we like it
Forward price vs. profit of 12.5x — cheap for medtech (sector trades at 18-25x). Dividend Aristocrat with 54 years of increases. Spin-off of Life Sciences completed in Feb 2026 generated $4B in cash for buying back their own shares and debt. BD Alaris received full FDA approval — unlocks upgrade cycle. BioPharma benefits from the GLP-1 boom (Ozempic, Mounjaro).
Key Risk
Tariffs impact 370 basis points in FY2026 due to manufacturing in Mexico. China pressures prices with volume purchase policies. Organic growth in Q1 was only 1.6%, needs to accelerate.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked BDX on Mar 23, 2026 at $156.23.
Full Research
Becton Dickinson (BDX) — Full Research
Price: $156.23 | P/E: 25.5 | Forward P/E: 12.5 | Div Yield: 2.69% | Market Cap: $44.4B
What is Becton Dickinson?
Becton Dickinson is the most essential medical device maker in the world. Every time a doctor draws your blood, they use a BD Vacutainer tube. Every time you get an injection, it's likely with a BD syringe. With 54 consecutive years of dividend increases, it is one of the most reliable Dividend Aristocrats in the S&P 500.
Business Segments (Post Spin-Off, Feb 2026)
| Segment | Est. Revenue | % Total | Description |
|---|---|---|---|
| Medical Essentials | ~$6.1B | 34% | Syringes, needles, BD Vacutainer, IV catheters, vascular access |
| Interventional | ~$5.0B | 28% | Surgery, urology, critical care, hernia repair |
| Connected Care | ~$4.5B | 25% | BD Alaris pumps, BD Pyxis dispensers, patient monitoring |
| BioPharma Systems | ~$2.3B | 13% | Pre-filled syringes for biologics/GLP-1s, auto-injectors |
Total revenue for New BD (pro forma): ~$17.8B. TAM: $70B+ growing ~5%.
Recent Results
FY2025 (fiscal year ended Sep 30, 2025):
- Revenue: $21.84B (+8.24% YoY)
- Net Income (GAAP): $1.68B
- EPS GAAP: $5.82 | Adjusted EPS: ~$13.14
- The GAAP vs adjusted difference reflects spin-off costs and acquisition amortization
Q1 FY2026 (quarter ended Dec 31, 2025):
- Revenue: $5.25B (+1.6%)
- Adjusted EPS: $2.91
- GAAP EPS: $1.34 (+28.8% YoY)
FY2026 Guidance:
- Revenue growth: low single-digit
- Adjusted EPS: $12.35 - $12.65 (~6% growth)
- Tariff impact: ~370 bps headwind
Dividend and Shareholder Return
- Annual Dividend: $4.20/share (~2.69% yield)
- Consecutive years of increase: 54 — Dividend Aristocrat
- 5-year dividend growth: 5.4% CAGR
- Payout ratio (on adjusted EPS): ~34% (very conservative)
- Spin-off generated $4B in cash for share buybacks and debt reduction
Competitive Advantages (Moat)
- Dominance in blood collection: BD Vacutainer holds 80%+ market share in the US
- Manufacturing scale: Produces billions of disposable devices annually — costs impossible to replicate
- BD Alaris: Installed in ~50% of US hospital beds — high switching cost
- BD Pyxis: Automatic dispensers in hospital pharmacies — locked-in
- Regulation as barrier: FDA approvals create years-long entry barriers for competitors
- BioPharma: Pharmaceutical companies rely on BD for pre-filled syringes for biologics — not easy to switch suppliers
Catalysts
- Spin-off completed (Feb 2026) — BD received $4B in cash, company more focused on pure medtech
- BD Alaris full FDA approval — Unlocks massive upgrade cycle in hospitals
- GLP-1 Boom — Ozempic, Mounjaro, Zepbound all need pre-filled syringes that BD manufactures
- Forward P/E of 12.5x — Medtech usually trades at 18-25x, BD is discounted due to transition
- $4B for buybacks — At these depressed prices, buybacks are very accretive
- Edwards Critical Care integration — AI patient monitoring in 10,000+ hospitals
Key Risks
- Tariffs: 370 bps headwind in FY2026 due to manufacturing in Mexico and other locations
- China VBP: Volume purchase policies pressure prices of Vacutainer and other products
- Slow organic growth: Q1 FY2026 was only +1.6%, needs to accelerate to mid-single-digit
- High debt: Acquisitions of C.R. Bard ($24B) and Edwards ($4.2B) left significant debt
- Competition in infusion pumps: ICU Medical and Baxter investing in next-gen smart pumps
Competitive Position
| Metric | BDX | ABT | MDT | BAX |
|---|---|---|---|---|
| Market Cap | $44B | $200B | $110B | $15B |
| Dividend Yield | 2.69% | 1.8% | 3.2% | 2.8% |
| Years of dividend growth | 54 | 52 | 47 | 5 |
| Forward P/E | 12.5x | 22x | 15x | 10x |
BDX is the cheapest of the Dividend Aristocrats in medtech.
Analyst Consensus
- Rating: Buy (Moderate Buy)
- Average price target: $200 - $212
- Target range: $183 - $270
- Implied upside: +28% from $156.23
Conclusion
BDX at $156.23 is a value buy in healthcare with exceptional defensive protection. At 12.5x forward earnings, you're buying the dominant maker of essential medical devices — with 54 years of growing dividends, strong regulatory moats, and multiple post spin-off catalysts. The main risk is short-term (tariffs, slow growth), but the underlying business is nearly recession-proof — hospitals don't stop buying syringes and blood tubes.
Research date: Mar 23, 2026 | Next review: Sep 2026
This is not financial advice.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.